BIOMAT Database Logo BIOMAT Database Logo

Chronic rejection in primary renal allograft recipients under cyclosporine-prednisone immunosuppressive therapy. 1991

R J Knight, and R H Kerman, and M Welsh, and D Golden, and L Schoenberg, and C T Van Buren, and R M Lewis, and B D Kahan
Department of Surgery, University of Texas Medical School, Houston 77030.

Although the introduction of cyclosporine-prednisone immunosuppression has improved early renal graft survival, chronic rejection remains a major cause of longterm graft dysfunction. This study retrospectively examined 69 cases of chronic rejection among 643 primary renal allograft recipients treated with cyclosporine-prednisone immunosuppression from July 1981 to October 1989. Chronic rejection was defined as a rejection episode diagnosed greater than 90 days posttransplantation with characteristics of progressive nonacute renal function deterioration, confirmed, in most cases, by renal biopsy. This group was compared with an equal-sized matched cohort. Among cadaveric recipients, 61 of 456 patients (13.4%) displayed chronic rejection, whereas among living-related recipients, 8 of 187 patients (4.3%) developed chronic rejection. The average time from the date of transplantation to diagnosis of chronic rejection was 15 +/- 14 months. One- and three-year graft survivals following diagnosis of chronic rejection were 51% (30/59) and 25% (13/51), respectively, compared with the cohort one- and three-year graft survivals of 98% (58/59) and 86% (32/37) at similar periods posttransplantation. HLA mismatch, PRA status, blood transfusion history, lipid levels, cyclosporine trough levels, incidence of prior acute rejection, and initial graft dysfunction were not significantly different between the chronic rejection group and the matched cohort. Hypertension and proteinuria were significantly associated with chronic rejection (P less than 0.001). Of 58 biopsies performed, findings solely consistent with chronic rejection were observed in 9 cases (15%) and "acute upon chronic" rejection in 49 cases (83%). Treatment of acute concomitants improved the renal function in 43% (27/63) by the time of hospital discharge. Nonetheless, at 12 months the incidence of improved renal function eroded to 22% (13/59), suggesting that the benefit was relatively short-lived. Although the overall incidence of chronic rejection in this group of cyclosporine-prednisone-treated patients was lower than previous azathioprine-prednisone cohorts, the clinical presentation and progression of chronic rejection was similar. Additionally, the incidence of chronic rejection within this series was lower among living-related recipients versus cadaveric recipients of donor organs.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D007518 Isoantibodies Antibodies from an individual that react with ISOANTIGENS of another individual of the same species. Alloantibodies
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D001803 Blood Transfusion The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed) Blood Transfusions,Transfusion, Blood,Transfusions, Blood
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D003524 Cyclosporins A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection. Cyclosporines
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D006648 Histocompatibility The degree of antigenic similarity between the tissues of different individuals, which determines the acceptance or rejection of allografts. HLA Incompatibility,Histoincompatibility,Human Leukocyte Antigen Incompatibility,Immunocompatibility,Tissue Compatibility,Compatibility, Tissue,HLA Incompatibilities,Histocompatibilities,Histoincompatibilities,Immunocompatibilities,Incompatibility, HLA,Tissue Compatibilities

Related Publications

R J Knight, and R H Kerman, and M Welsh, and D Golden, and L Schoenberg, and C T Van Buren, and R M Lewis, and B D Kahan
Treatment of chronic renal allograft rejection with cyclosporine and prednisone.
January 1988, Transplantation,
R J Knight, and R H Kerman, and M Welsh, and D Golden, and L Schoenberg, and C T Van Buren, and R M Lewis, and B D Kahan
Determinants of chronic renal allograft rejection in cyclosporine-treated recipients.
November 1996, Transplantation,
R J Knight, and R H Kerman, and M Welsh, and D Golden, and L Schoenberg, and C T Van Buren, and R M Lewis, and B D Kahan
Chronic renal allograft rejection and cyclosporine.
October 1988, Transplantation proceedings,
R J Knight, and R H Kerman, and M Welsh, and D Golden, and L Schoenberg, and C T Van Buren, and R M Lewis, and B D Kahan
Cyclosporine therapy or dietary protein manipulation in chronic renal allograft rejection.
June 1988, Transplantation proceedings,
R J Knight, and R H Kerman, and M Welsh, and D Golden, and L Schoenberg, and C T Van Buren, and R M Lewis, and B D Kahan
Use of cyclosporine in chronic renal allograft rejection.
November 1988, Transplantation,
R J Knight, and R H Kerman, and M Welsh, and D Golden, and L Schoenberg, and C T Van Buren, and R M Lewis, and B D Kahan
A retrospective analysis of long-term renal allograft function associated with cyclosporine-prednisone immunosuppressive therapy.
June 1988, Transplantation proceedings,
R J Knight, and R H Kerman, and M Welsh, and D Golden, and L Schoenberg, and C T Van Buren, and R M Lewis, and B D Kahan
Immunosuppressive metabolites of cyclosporine in the blood of renal allograft recipients.
September 1986, Transplantation,
R J Knight, and R H Kerman, and M Welsh, and D Golden, and L Schoenberg, and C T Van Buren, and R M Lewis, and B D Kahan
Risk of acute cellular rejection after azathioprine withdrawal in stable renal allograft recipients on cyclosporine, azathioprine, and prednisone.
June 1998, Transplantation proceedings,
R J Knight, and R H Kerman, and M Welsh, and D Golden, and L Schoenberg, and C T Van Buren, and R M Lewis, and B D Kahan
An increased incidence of late acute rejection episodes in cadaver renal allograft recipients given azathioprine, cyclosporine, and prednisone.
August 1990, Transplantation,
R J Knight, and R H Kerman, and M Welsh, and D Golden, and L Schoenberg, and C T Van Buren, and R M Lewis, and B D Kahan
Risk factors for chronic rejection in renal allograft recipients.
April 1993, Transplantation,
Copied contents to your clipboard!